Flag of the European Union EU Clinical Trials Register Help

Clinical trials for class II gene

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: class II gene. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2017-004310-25 Sponsor Protocol Number: ARRAY-797-301 Start Date*: 2018-12-14
    Sponsor Name:Array BioPharma Inc.
    Full Title: A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 in Patients with Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
    Medical condition: Dilated Cardiomyopathy (DCM) with Lamin A/C protein (LMNA) Mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10056419 Dilated cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NO (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000789-31 Sponsor Protocol Number: RGH201 Start Date*: 2018-02-09
    Sponsor Name:Kuopio University Hospital Heart Center
    Full Title: Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory angina. A phase II randomized, double-blinded, placebo-controlled s...
    Medical condition: Refractory angina
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064262 Refractory angina pectoris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004457-15 Sponsor Protocol Number: EMD 121974-012 Start Date*: 2010-08-13
    Sponsor Name:Merck KGaA
    Full Title: Cilengitide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter - a multicenter, open-label Phase II study, investigating two cilengitide regimens in combin...
    Medical condition: Newly diagnosed glioblastoma multiforme with unmethylated MGMT gene promoter status
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Prematurely Ended) FR (Completed) HU (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003858-85 Sponsor Protocol Number: HFIRONT Start Date*: 2020-02-24
    Sponsor Name:Medical University Innsbruck
    Full Title: Randomized double-blind explorative controlled clinical trial analyzing the effects of ferric carboxymaltose in patients with iron deficiency and chronic heart failure
    Medical condition: This is a randomized double-blind explorative controlled clinical Trial that analyses the effects of 1000mg ferric carboxymaltose in patients with chronic heart failure and iron deficiency.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005803-16 Sponsor Protocol Number: GITMOAMLR.2 Start Date*: 2007-12-24
    Sponsor Name:GITMO (GRUPPO ITALIANO DI MIDOLLLO OSSEO)
    Full Title: RANDOMIZED STUDY COMPARING INTRAVENOUS BUSULFAN (I.V. BU; BUSILVEX) PLUS FLUDARABINE (BUFLU) VERSUS INTRAVENOUS BUSULFAN PLUS CYCLOPHOSPHAMIDE (BUCY2) AS CONDITIONING REGIMENS PRIOR TO ALLOGENEIC H...
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002356-18 Sponsor Protocol Number: MC-FludT.14/L Start Date*: 2010-01-12
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in pa...
    Medical condition: Patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) considered ineligible to standard conditioning therapies prior to allogeneic stem cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000881 Acute myeloid leukaemia (in remission) PT
    20.0 100000013034 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) PL (Completed) FI (Prematurely Ended) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-012324-83 Sponsor Protocol Number: UZB-BN-09-001 Start Date*: 2009-07-04
    Sponsor Name:Prof Bart Neyns
    Full Title: CeCil: A randomized, non-comparative phase II clinical trial of the effect of radiation therapy plus Temozolomide combined with Cilengitide or Cetuximab on the 1-year overall survival of patients w...
    Medical condition: Subjects with newly diagnosed glioblastoma, who have met all eligibility criteria for the CENTRIC study (EMD 121974-011 study, EudraCT 2007-004344-78) with the exception of NOT having a tumor with ...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10018336 Glioblastoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001604-30 Sponsor Protocol Number: 1001 Start Date*: 2017-12-11
    Sponsor Name:Medical University of Vienna
    Full Title: Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial
    Medical condition: Antibody-mediated rejection of a kidney transplant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000250-94 Sponsor Protocol Number: MAST2 Start Date*: 2020-07-17
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Mutation-specific therapy for the long QT syndrome
    Medical condition: Long QT syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10057926 Long QT syndrome congenital PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006441-10 Sponsor Protocol Number: 116-02 Start Date*: 2009-06-03
    Sponsor Name:SCIPHARM SáRL
    Full Title: A double blind controlled clinical study to investigate the efficacy and tolerability of subcutaneous Treprostinil sodium in patients with severe non-operable Chronic Thromboembolic Pulmonary Hyper...
    Medical condition: Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) SK (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006609-25 Sponsor Protocol Number: MOOD-HF Start Date*: 2008-05-27
    Sponsor Name:Julius Maximilians Universität Würzburg
    Full Title: Effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in Depressed Heart Failure patients
    Medical condition: To investigate the effects of selective serotonin re-uptake inhibition with the SSRI escitalopram on morbidity and mortality in depressed patients with CHF. The primary endpoint is the time to a fi...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000394-60 Sponsor Protocol Number: ACR16C007 Start Date*: 2004-06-30
    Sponsor Name:A. Carlsson Research AB
    Full Title: A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease
    Medical condition: ACR16 belongs to a new class of CNS active agents called dopaminergic stabilizers. Dopaminergic stabilizers are compounds that can both enhance and counteract dopamine dependent functions in the CN...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004567-11 Sponsor Protocol Number: 75911 Start Date*: 2020-12-08
    Sponsor Name:Zealand University Hospital
    Full Title: Effect of Low-dose Interferon-alfa2a on peri operative immune suppression
    Medical condition: pMMR Colon cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001833-15 Sponsor Protocol Number: ASLAN001-012 Start Date*: 2017-09-29
    Sponsor Name:ASLAN Pharmaceuticals
    Full Title: A Two-Part Phase 2/3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Of Varlitinib Plus mFOLFOX6 Versus Placebo Plus mFOLFOX6 in Subjects with HER1/ HER2 Co-Expressing Advanced or M...
    Medical condition: HER1/ HER2 Co-Expressing Advanced or Metastatic Gastric Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) EE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004730-11 Sponsor Protocol Number: KMT2021001 Start Date*: 2022-02-18
    Sponsor Name:Medical University of Vienna
    Full Title: A prospective, controlled, single-arm pilot study on treosulfan, fludarabine, and cyclophosphamide (TreoFC) as conditioning treatment before haploidentical hematopoietic stem cell transplantation f...
    Medical condition: Conditioning therapy before haploidentical hematopoietic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004865 10059044 Allogeneic peripheral hematopoietic stem cell transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003536-92 Sponsor Protocol Number: CY6031 Start Date*: 2022-05-09
    Sponsor Name:Cytokinetics, Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventric...
    Medical condition: obstructive hypertrophic cardiomyopathy (oHCM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) ES (Ongoing) NL (Completed) CZ (Completed) PL (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002793-91 Sponsor Protocol Number: Pervision Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital Tuebingen
    Full Title: Prospective phase I/II trial of an individualized peptide vaccine in pediatric and AYA patients with metastasized fusion-driven sarcomas following standard treatment
    Medical condition: The trial will include patients with so called "fusion-driven", metastatic sarcomas of the following types: - Ewing sarcoma, - alveolar rhabdomyosarcoma - or synovial sarcoma who are in first or s...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065867 Alveolar rhabdomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002857-41 Sponsor Protocol Number: BORTEJECT Start Date*: 2013-07-11
    Sponsor Name:Universitätsklinik für Innere Medizin III, Medizinische Universität Wien
    Full Title: Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study)
    Medical condition: Late antibody-mediated kidney allograft rejection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001252-35 Sponsor Protocol Number: DANA-2018-1. Start Date*: 2018-09-06
    Sponsor Name:Kirsten Møller
    Full Title: Neuroplasticity induced by general anaesthesia
    Medical condition: This trial investigates the effects of general anaesthesia on the helathy human brain. Thus, only healthy, young adults with no medical conditions will participate as volunteers in this study.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000545-40 Sponsor Protocol Number: FELZ01 Start Date*: 2021-08-01
    Sponsor Name:Medical University of Vienna
    Full Title: Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection – A Phase 2 Pilot Trial
    Medical condition: Late active or chronic active antibody-mediated rejection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:45:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA